109 related articles for article (PubMed ID: 15286719)
1. Transcriptional activation of c-myc proto-oncogene by WT1 protein.
Han Y; San-Marina S; Liu J; Minden MD
Oncogene; 2004 Sep; 23(41):6933-41. PubMed ID: 15286719
[TBL] [Abstract][Full Text] [Related]
2. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
3. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
Zhang X; Xing G; Saunders GF
Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
7. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
[TBL] [Abstract][Full Text] [Related]
8. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
9. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
10. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun.
Dejong V; Degeorges A; Filleur S; Ait-Si-Ali S; Mettouchi A; Bornstein P; Binétruy B; Cabon F
Oncogene; 1999 May; 18(20):3143-51. PubMed ID: 10340386
[TBL] [Abstract][Full Text] [Related]
11. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
12. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1.
Wagner N; Wagner KD; Xing Y; Scholz H; Schedl A
J Am Soc Nephrol; 2004 Dec; 15(12):3044-51. PubMed ID: 15579507
[TBL] [Abstract][Full Text] [Related]
13. The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells.
Yang X; Liu D; Murray TJ; Mitchell GC; Hesterman EV; Karchner SI; Merson RR; Hahn ME; Sherr DH
Oncogene; 2005 Nov; 24(53):7869-81. PubMed ID: 16091746
[TBL] [Abstract][Full Text] [Related]
14. Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1.
Rae FK; Martinez G; Gillinder KR; Smith A; Shooter G; Forrest AR; Grimmond SM; Little MH
Oncogene; 2004 Apr; 23(17):3067-79. PubMed ID: 15021918
[TBL] [Abstract][Full Text] [Related]
15. Expression of the TAF4b gene is induced by MYC through a non-canonical, but not canonical, E-box which contributes to its specific response to MYC.
Teye K; Okamoto K; Tanaka Y; Umata T; Ohnuma M; Moroi M; Kimura H; Tsuneoka M
Int J Oncol; 2008 Dec; 33(6):1271-80. PubMed ID: 19020761
[TBL] [Abstract][Full Text] [Related]
16. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo.
Wagner N; Michiels JF; Schedl A; Wagner KD
Oncogene; 2008 Jun; 27(26):3662-72. PubMed ID: 18212735
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
[TBL] [Abstract][Full Text] [Related]
18. Activation of the WT1 tumor suppressor gene promoter by Pea3.
Discenza MT; Vaz D; Hassell JA; Pelletier J
FEBS Lett; 2004 Feb; 560(1-3):183-91. PubMed ID: 14988020
[TBL] [Abstract][Full Text] [Related]
19. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway.
Ito K; Oji Y; Tatsumi N; Shimizu S; Kanai Y; Nakazawa T; Asada M; Jomgeow T; Aoyagi S; Nakano Y; Tamaki H; Sakaguchi N; Shirakata T; Nishida S; Kawakami M; Tsuboi A; Oka Y; Tsujimoto Y; Sugiyama H
Oncogene; 2006 Jul; 25(30):4217-29. PubMed ID: 16518414
[TBL] [Abstract][Full Text] [Related]
20. VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.
Cash J; Korchnak A; Gorman J; Tandon Y; Fraizer G
Oncol Rep; 2007 Jun; 17(6):1413-9. PubMed ID: 17487399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
